By Ikon Kim
May 26, 2026 · 3 min readNovo Nordisk's first oral semaglutide pill for weight loss hit U.S. pharmacies in January 2026 at $149 a month, even as state insurers and large employers stripped the same GLP-1 drugs from worker plans.
The split exposes a widening class divide in obesity care, where wealthier patients buy access while public workers and low-income Americans watch the same treatments slip out of reach.
Obesity now reaches a record 40% of American adults, and GLP-1 medications cut diabetes risk, heart disease, and stroke alongside weight loss, raising the long-term stakes of every coverage decision.
GLP-1 drugs, the class that includes Mounjaro and Wegovy, mimic gut hormones to suppress appetite and slow digestion, delivering weight loss on a scale that earlier diet medications never matched.
According to Scientific American, the pill starts at $149 monthly for the lowest dose and climbs to $299 for the highest, well below the $349 cash price for injectable Wegovy.
Wegovy redrew obesity care after winning FDA weight-loss approval in 2021, igniting an injectable boom that public payers now move to roll back.
Patients on the highest pill dose dropped 16.6% of body weight over 68 weeks of late-stage trials, performance nearly matching the 17.4% loss recorded for Wegovy.
Massachusetts moved the other direction in February 2026, when the state commission voted 10-7 to drop weight-loss GLP-1 coverage for 460,000 workers, retirees, and family members starting July 2026.
The pullback echoes a broader employer trend, with roughly 55% of commercial plans currently covering GLP-1s for obesity, according to JPMorgan Research.
GLP-1 prescriptions drove about a third of last year's nearly 12% premium jump in the Massachusetts plan, leaving 22,000 weight-loss patients to absorb the change Governor Maura Healey ordered.
Fewer than one-third of U.S. insurers currently cover GLP-1 medications for weight loss, the USC Schaeffer Center reported, leaving most Americans to pay full retail or go without.
Alison Sexton Ward, a research scientist at the center, projected $175 billion to $245 billion in federal savings over a decade through fewer hospitalizations and nursing-home stays, with returns exceeding 13% a year on the federal investment.
Across the Atlantic, a recent study led by King's College London found NHS eligibility rules will reach only 200,000 patients over three years, while 1.5 million Britons buy treatment privately.
Laurence Dobbie, a researcher on the team, warned that the BMI-40-plus threshold concentrates access among people already paying for private clinics, deepening what the team called a postcode lottery.
A November 2025 Cureus paper measured the gap directly, reporting semaglutide costs $936 a month in the United States, $93 in the United Kingdom, and just $51 in Croatia.
The authors, physicians at hospitals in Melbourne and northeast England, invoked Julian Tudor Hart's 1971 inverse care law to argue that access tracks money rather than medical need.
About half of insured Americans on the drugs reported difficulty paying for them in a November 2025 KFF poll, a figure that holds even before the latest plan cuts take effect across state and municipal payrolls.
Demand keeps climbing regardless, with JPMorgan analysts projecting 30 million U.S. patients on GLP-1s by 2030, triple the roughly 10 million figure for 2025.
Stopping the drugs triggers weight cycling and brings back high cholesterol, high blood sugar, and high blood pressure, the Cureus authors noted, meaning short-term coverage cuts shift costs forward rather than erasing them.
Medicare begins covering select GLP-1s in July 2026 with a $50 monthly copay, though commercial coverage continues to vary by employer.
The heaviest obesity burden falls on the very groups least likely to reach the pharmacy counter.
Black and Hispanic populations register obesity rates near 53% and 43%, respectively, deepening the equity gap that pharmacological price drops have only partly addressed.
